Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07686588Phase 2Not yet recruiting
- Sponsor
- Wuhan Biying Biotechnology
- Start
- Jul 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in head and neck squamous cell carcinoma (HNSCC), sponsored by Wuhan Biying Biotechnology. Primary endpoint: Objective Response Rate up to 24 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07686588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686588.